US4454140A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nasal administration of dextromethorphan
Assignee: Hoffmann La Roche Inc
•
Filing: 1982-09-07
•
Granted: 1984-06-12
•
Expires: 2002-09-07
Abstract
Abstract The invention relates to a novel method of administering dextromethorphan, a known anti-tussive agent used for the suppresion of coughs due to colds and allergies. The novel method utilizes dosage forms of dextromethorphan which are adapted for nasal administration.
Inventors
- 👤 Arthur H. Goldberg
- 👤 Meyer Matluck
- 👤 Joseph A. Ranucci
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 11:50
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
38 words
A method for reducing the incidence of coughs which comprises nasally administering to a warm-blooded animal requiring antitussive therapy, a therapeutically effective amount of a compound of the formula ##STR2## or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Independent Claim
38 words
A method for reducing the incidence of coughs which comprises nasally administering to a warm-blooded animal requiring antitussive therapy, a therapeutically effective amount of a compound of the formula ##STR2## or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
20 words
The method as defined in claim 1, wherein said compound is nasally administered with a nontoxic pharmaceutically acceptable nasal carrier.
Claim 4
Dependent Claim
31 words
The method as defined in claim 2 wherein the amount of dextromethorphan is about 0.005 parts by weight to about 1 part by weight per part by weight of carrier material.
Claim 5
Dependent Claim
24 words
The method as defined in claim 3 wherein the amount of dextromethorphan is about 0.01 to about 0.2 parts by weight of carrier material.
Claim 6
Dependent Claim
31 words
The method as defined in claim 2, wherein said compound is administered from a dosage form selected from the group consisting of nasal solution, nasal suspension, nasal ointment, and nasal gel.
Claim 7
Dependent Claim
18 words
The method as defined in claim 3 wherein said compound is administered from a nasal solution dosage form.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-12 | 1987-12-12 | 1988-06-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-12 | 1991-12-12 | 1992-06-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-12 | 1995-12-12 | 1996-06-12 | $7700.00 | Window Closed / Lapsed |